As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth potential. One area drawing attention is the Russell 2000 Index, which tracks 2,000 U.S. small-cap stocks. In this article, we spotlight three standout names: Syndax Pharmaceuticals (SNDX), Nuvation Bio (NUVB), and Aura Biosciences (AURA).
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Each of these companies is focused on developing cancer treatments and has earned Strong Buy ratings from analysts, thanks to their promising pipelines and significant upside potential. Let’s dive into the details.
Is Syndax a Good Stock to Buy?
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on developing and delivering innovative cancer treatments. Year-to-date, SNDX stock has declined by nearly 28%.
Yesterday, Goldman Sachs initiated its coverage on SNDX stock with a Buy rating, projecting a potential upside of almost 90%. Overall, eight out of nine analysts currently covering the stock have issued Buy recommendations. Meanwhile, the average Syndax stock price target of $31.25 suggests a 229% upside from current levels.
Is Nuvation Bio a Good Buy?
Nuvation Bio is a global drug company working to treat some of the toughest cancers by creating new and unique cancer medicines. Year-to-date, NUVB stock has declined by nearly 15%.
This week, RBC Capital reiterated its Buy rating on NUVB stock, predicting an upside of over 160%. Overall, on TipRanks, NUVB has unanimous Buy recommendations from six analysts covering the stock. Meanwhile, Nuvation Bio’s average price target of $7.4 suggests a potential upside of 227% from current levels.
Is AURA a Good Stock to Buy?
Aura Biosciences is a clinical-stage biotech company developing a new type of cancer treatment called virus-like drug conjugates (VDCs) to target different types of cancer. With promising early clinical data and a focus on hard-to-treat cancers like ocular melanoma, the company could offer strong long-term upside potential for investors.
According to TipRanks, Aura Biosciences holds a Strong Buy consensus rating from Wall Street, with all six analysts recommending a Buy. Taken together, Aura Biosciences’ stock forecast of $21.75 implies an upside of about 230%.
Year-to-date, AURA stock has declined by almost 20%.
